Pinning down potential new opportunities for IL–8 and 4–1BB
The keynote address at the 2018 CRI CIMT EATI AACR International Cancer Immunotherapy Conference in New York last month was given by Ignacio Melero (Pamplona). Professor Melero gave an engaging and informative presentation entitled, “The immunotherapy faces of Interleukin–8 and CD137.” He also had a related talk on “4–1BB and Metabolism” at the Society for Immunotherapy of Cancer (SITC) meeting this weekend.
Pinning down new opportunities in IL-8 and 4-1BB
The late and sadly missed, Dr Holbrook Kohrt (Stanford), worked closely with Prof Melero on targeting CD137 or 4–1BB, as it’s more commonly known.
Regular readers may recall our interview wth Dr Kohrt back at Immunology 2015 in New Orleans (Link).
If you missed it, we also shared some excerpts from this discussion on Episode 6 of the Novel Targets Podcast, “Stepping on the Gas” (Link). There was also a tribute to Dr Kohrt from Dr Ron Levy (Stanford) at the start of Episode 11 of the podcast (Link).
Professor Melero kindly spoke to BSB at SITC 2018 and shared his thoughts on where we are three years on and where his research is currently focused in relation to cytokines, and in particular, IL–8.
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
He was a Stanford hematologist/oncologist and rising star in the cancer immunotherapy field. Our thoughts go out to his family and friends.